Santen Pharmaceutical
Santen Pharmaceutical Co., Ltd., commonly known as Santen, is a leading global ophthalmic pharmaceutical company headquartered in Japan. Established in 1890, Santen has a rich history of innovation in the eye care industry, focusing on the development and marketing of prescription pharmaceuticals and medical devices. With a strong presence in major operational regions including Europe, North America, and Asia, Santen is dedicated to improving the quality of life for patients with eye diseases. The company’s core product offerings include treatments for glaucoma, dry eye, and retinal diseases, distinguished by their commitment to research and development. Santen's unique approach combines advanced technology with a deep understanding of patient needs, positioning it as a trusted leader in ophthalmology. Notable achievements include a robust pipeline of innovative therapies and a strong market presence, underscoring Santen's dedication to advancing eye health globally.
DitchCarbon Score
How does Santen Pharmaceutical's carbon action stack up? DitchCarbon scores companies based on their carbon action and commitment to reducing emissions. Read about our methodology to learn more.
Industry Average
Mean score of companies in the Medical Device Manufacturing industry. Comparing a company's score to the industry average can give you a sense of how well the company is doing compared to its peers.
Industry Benchmark
Santen Pharmaceutical's score of 42 is higher than 94% of the industry. This can give you a sense of how well the company is doing compared to its peers.
Santen Pharmaceutical's reported carbon emissions
In 2023, Santen Pharmaceutical, headquartered in Japan, reported total greenhouse gas emissions of approximately 22,438,000 kg CO2e, which includes 16,948,000 kg CO2e from Scope 1 and 5,671,000 kg CO2e from Scope 2 emissions. The company has set ambitious climate commitments, aiming to reduce its absolute Scope 1 and 2 greenhouse gas emissions by 50% by FY 2030, using FY 2019 as the baseline. Additionally, Santen plans to cut its Scope 3 emissions from purchased goods and services by 15% within the same timeframe. These targets align with the Science Based Targets initiative (SBTi) and are designed to contribute to limiting global warming to 1.5°C. Santen's ongoing efforts reflect a commitment to sustainability and responsible environmental stewardship within the pharmaceutical industry.
Unlock detailed emissions data
Access structured emissions data, company-specific emission factors, and source documents
Add to project| 2007 | 2008 | 2009 | 2010 | 2011 | 2019 | 2020 | 2021 | 2022 | 2023 | |
|---|---|---|---|---|---|---|---|---|---|---|
| Scope 1 | 34,100,000 | 00,000,000 | 00,000,000 | 00,000,000 | 00,000,000 | - | 00,000,000 | 00,000,000 | 00,000,000 | 00,000,000 |
| Scope 2 | 34,100,000 | 00,000,000 | 00,000,000 | 00,000,000 | 00,000,000 | - | 00,000,000 | 00,000,000 | 0,000,000 | 0,000,000 |
| Scope 3 | 34,100,000 | 00,000,000 | 00,000,000 | 00,000,000 | 00,000,000 | - | 000,000,000 | 000,000,000 | 000,000,000 | 000,000,000 |
Industry emissions intensity
Location emissions intensity
Reduction initiatives & disclosure networks
Companies disclose and commit to reducing emissions to show they are serious about reducing emissions impact over time. They can also help a company track its progress over time.
Santen Pharmaceutical is committed to some reduction initiatives we track. This may change over time as the company engages with new initiatives or updates its commitments. DitchCarbon will update this information as it becomes available.
